Dupilumab-Induced Follicular Conjunctivitis

Ocul Immunol Inflamm. 2019;27(8):1339-1341. doi: 10.1080/09273948.2018.1533567. Epub 2018 Oct 18.

Authors

Elizabeth Shen¹, Kate Xie¹, Kevin Jwo¹, Janellen Smith², Sameh Mosaed¹

Affiliations

¹ Ophthalmology, Gavin Herbert Eye Institute, UC Irvine Health, Irvine, California, USA.
² Dermatology, UC Irvine Health, Orange, California, USA.

PMID: 30335586
DOI: 10.1080/09273948.2018.1533567

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Conjunctivitis / chemically induced*
Conjunctivitis / diagnosis
Conjunctivitis / drug therapy
Cyclosporine / therapeutic use
Dermatitis, Atopic / drug therapy
Drug Therapy, Combination
Female
Glucocorticoids / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Interleukin-4 Receptor alpha Subunit / immunology
Male
Olopatadine Hydrochloride / therapeutic use
Prednisolone / analogs & derivatives
Prednisolone / therapeutic use
Slit Lamp Microscopy

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal, Humanized
Glucocorticoids
Immunosuppressive Agents
Interleukin-4 Receptor alpha Subunit
Olopatadine Hydrochloride
dupilumab
Cyclosporine
prednisolone acetate
Prednisolone